These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8582956)

  • 21. Gonadotropin levels in women with polycystic ovary syndrome: their relationship to body weight and insulin levels.
    Tropeano G; Vuolo IP; Lucisano A; Liberale L; Barini A; Carfagna P; Caroli G; Menini E; dell'Acqua S
    J Endocrinol Invest; 1996 Mar; 19(3):139-45. PubMed ID: 8743278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome.
    Ciampelli M; Fulghesu AM; Cucinelli F; Pavone V; Caruso A; Mancuso S; Lanzone A
    Hum Reprod; 1997 Sep; 12(9):1897-901. PubMed ID: 9363702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dysfunction of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovarian syndrome.
    Piaditis GP; Kounadi TG; Rangou DB; Trovas GP; Kaklas NA; Tzonou AJ; Chlouverakis CS
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):635-40. PubMed ID: 7634505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of ovary suppression by a long-acting GnRH-agonist on circulating GH, insulin-like growth factor I and insulin levels in women with polycystic ovary syndrome.
    Tropeano G; Liberale I; Vuolo IP; Barini A; Caroli G; Carfagna P; Menini E
    J Endocrinol Invest; 1997 Apr; 20(4):220-4. PubMed ID: 9211130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of oral glucose administration on plasma growth hormone levels in women with polycystic ovary syndrome.
    Tropeano G; Barini A; Caroli G; Carfagna P; Vuolo IP; Novelli P; Rossodivita A; Lucisano A; Lanzone A
    Fertil Steril; 1997 Dec; 68(6):987-91. PubMed ID: 9418684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The counterregulatory response to hypoglycaemia in women with the polycystic ovary syndrome.
    Gennarelli G; Holte J; Stridsberg M; Niklasson F; Berne C; Bäckström T
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):167-74. PubMed ID: 9135698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion.
    Lanzone A; Fulghesu AM; Cucinelli F; Ciampelli M; Caruso A; Mancuso S
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3501-6. PubMed ID: 8530590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
    Insler V; Barash A; Shoham Z; Koistinen R; Seppala M; Hen M; Lunenfeld B; Zadik Z
    Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist.
    Lanzone A; Fulghesu AM; Andreani CL; Apa R; Fortini A; Caruso A; Mancuso S
    Hum Reprod; 1990 Feb; 5(2):143-9. PubMed ID: 2108986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.
    Grottoli S; Procopio M; Maccario M; Zini M; Oleandri SE; Tassone F; Valcavi R; Ghigo E
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2261-5. PubMed ID: 9215304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
    Lanzi R; Luzi L; Caumo A; Andreotti AC; Manzoni MF; Malighetti ME; Sereni LP; Pontiroli AE
    Metabolism; 1999 Sep; 48(9):1152-6. PubMed ID: 10484056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The inhibitory effect of glucose on growth hormone secretion is lost in obesity but not in hypertension.
    Limone P; Oleandri SE; Ajmone Catt P; Grottoli S; Frangioni C; Avogadri E; Perrin M; Valetto MR; Maccario M
    J Endocrinol Invest; 1997 Nov; 20(10):616-20. PubMed ID: 9438920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of gonadotrophin-releasing hormone agonist treatment on growth hormone secretion in women with polycystic ovarian syndrome.
    Kaltsas T; Pontikides N; Krassas GE; Seferiadis K; Lolis D; Messinis IE
    Hum Reprod; 1998 Jan; 13(1):22-6. PubMed ID: 9512222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin and GH secretion in adolescent girls with irregular cycles: polycystic vs multifollicular ovaries.
    Villa P; Rossodivita A; Fulghesu AM; Cucinelli F; Barini A; Apa R; Belosi C; Lanzone A
    J Endocrinol Invest; 2003 Apr; 26(4):305-11. PubMed ID: 12841537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth hormone and somatomedin-C secretion in patients with polycystic ovarian disease. Their relationships with hyperinsulinism and hyperandrogenism.
    Lanzone A; Fulghesu AM; Pappalardo S; Proto C; Le Donne M; Andreani CL; Muscatello R; Caruso A; Mancuso S
    Gynecol Obstet Invest; 1990; 29(2):149-53. PubMed ID: 2110544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone response to L-dopa and pyridostigmine in women with polycystic ovarian syndrome.
    Lee EJ; Lee BS; Lee HC; Park KH; Song CH; Huh KB
    Fertil Steril; 1993 Jul; 60(1):53-7. PubMed ID: 8513959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X; Lin JF
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
    Sepilian V; Nagamani M
    J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.